AMLX
Amylyx Pharmaceuticals, Inc.
There isn't enough reported data to score AMLX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
AMLX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Strong |
AMLX's balance sheet is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMLX PE Valuation
AMLX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AMLX Forward outlook
There aren't enough analyst estimates for AMLX to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
AMLX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.42 | +$0.38 |
| Q2 2026 | -$1.41 | +$1.09 |
| Q1 2026 | -$1.48 | +$1.63 |
| Q4 2025 | -$1.53 | +$2.91 |
| Q3 2025 | -$1.80 | +$2.02 |
| Q2 2025 | -$2.50 | -$0.05 |
| Q1 2025 | -$3.11 | -$2.04 |
| Q4 2024 | -$4.44 | -734% |
AMLX is still losing money, but far less than before: $1.42 per share over the past year, against $4.44 at its worst in late 2024.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over AMLX on earnings quality, reporting a profit while its opponent remains loss making.
AMLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2024 | $416K | -100% |
| Q1 2024 | $88.6M | +24% |
| Q4 2023 | $108.4M | +396% |
| Q3 2023 | $102.7M | +29666% |
LLY has the stronger quarterly revenue trend. Revenue is down 100% for AMLX versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2024 | -18188% | -18206 points |
| Q1 2024 | -138% | -135 points |
| Q4 2023 | 1.8% | +206 points |
| Q3 2023 | 18% | +15868 points |
| Q2 2023 | 21% | N/A |
| Q1 2023 | -2.9% | N/A |
| Q4 2022 | -204% | N/A |
| Q3 2022 | -15850% | N/A |
AMLX's operating margin was −18188% last quarter, down 18208 points from the same quarter a year ago, near the bottom of its range since 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
AMLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$33.7M | -$3.3M |
| Q4 2025 | -$28M | +$31M |
| Q3 2025 | -$30.4M | +$11.2M |
| Q2 2025 | -$25.3M | +$41.4M |
| Q1 2025 | -$39.8M | -$39.3M |
| Q4 2024 | -$59M | -547% |
| Q3 2024 | -$41.6M | -$36M |
| Q2 2024 | -$66.7M | -900% |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with AMLX at down 8.1%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
AMLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7% | +7.7M shares |
| 1 year | +27% | +25.6M shares |
| 3 years | +71% | +49.2M shares |
| 5 years | +115% | +63.7M shares |
AMLX has 119M diluted shares, up 27% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q2 2024 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AMLX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AMLX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -4.3x | Net Cash |
AMLX has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AMLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.1 | Neutral |
| Stochastic | 45.5 | Neutral |
AMLX's weekly RSI is 61 (neutral) and its Stochastic is 46 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AMLX PE vs Healthcare Sector
| Metric | AMLX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AMLX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AMLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.4 | 5.1% above |
| 20 week MA | $26.8 | 12% above |
| 50 week MA | $19.4 | 54% above |
| 100 week MA | $13.4 | 124% above |
| 200 week MA | $14.0 | 114% above |
AMLX has climbed back above all five of its weekly moving averages, and it's now 114% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
AMLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $18.1 | $35.6 | +97% |
| 2023 | $35.6 | $14.7 | -59% |
| 2024 | $14.7 | $3.87 | -74% |
| 2025 | $3.87 | $12.3 | +219% |
| 2026 YTD | $12.3 | $29.9 | +142% |
AMLX has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.